Arix Bioscience Holdings Ltd - Net Worth and Insider Trading

Arix Bioscience Holdings Ltd Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Arix Bioscience Holdings Ltd owns 4 companies in total, including LogicBio Therapeutics Inc (LOGC) , Harpoon Therapeutics Inc (HARP) , and Imara Inc (IMRA) among others .

Click here to see the complete history of Arix Bioscience Holdings Ltd’s form 4 insider trades.

Insider Ownership Summary of Arix Bioscience Holdings Ltd

Ticker	Comapny	Transaction Date	Type of Owner
LOGC	LogicBio Therapeutics Inc	2018-10-18	10 percent owner
HARP	Harpoon Therapeutics Inc	2019-02-07	10 percent owner
IMRA	Imara Inc	2020-03-11	10 percent owner
		2020-03-11	10 percent owner

Arix Bioscience Holdings Ltd Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Arix Bioscience Holdings Ltd Ownership Network

Ownership Network List of Arix Bioscience Holdings Ltd

No Data

Ownership Network Relation of Arix Bioscience Holdings Ltd

Arix Bioscience Holdings Ltd Owned Company Details

What does LogicBio Therapeutics Inc do?

Who are the key executives at LogicBio Therapeutics Inc?

Arix Bioscience Holdings Ltd is the 10 percent owner of LogicBio Therapeutics Inc. Other key executives at LogicBio Therapeutics Inc include Chief Scientific Officer Mariana Nacht , Chief Medical Officer Daniel Gruskin , and Interim CFO Joshua Blacher .

LogicBio Therapeutics Inc (LOGC) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of LogicBio Therapeutics Inc (LOGC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of LogicBio Therapeutics Inc (LOGC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

LogicBio Therapeutics Inc (LOGC)'s detailed insider trading history can be found in Insider Trading Tracker table.

LogicBio Therapeutics Inc Insider Transactions

No Available Data

What does Harpoon Therapeutics Inc do?

Who are the key executives at Harpoon Therapeutics Inc?

Arix Bioscience Holdings Ltd is the 10 percent owner of Harpoon Therapeutics Inc. Other key executives at Harpoon Therapeutics Inc include 10 percent owner Vijay K Lathi , Chief Medical Officer Luke Nathaniel Walker , and Principal Fin. & Acctng Ofc. Frank J Lanza .

Harpoon Therapeutics Inc (HARP) Insider Trades Summary

Over the past 18 months, Arix Bioscience Holdings Ltd made no insider transaction in Harpoon Therapeutics Inc (HARP). Other recent insider transactions involving Harpoon Therapeutics Inc (HARP) include a net purchase of 21,397,205 shares made by Merck & Co., Inc. ,

In summary, during the past 3 months, insiders sold 0 shares of Harpoon Therapeutics Inc (HARP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Harpoon Therapeutics Inc (HARP) were sold and 21,397,205 shares were bought by its insiders, resulting in a net purchase of 21,397,205 shares.

Harpoon Therapeutics Inc (HARP)'s detailed insider trading history can be found in Insider Trading Tracker table.

Harpoon Therapeutics Inc Insider Transactions

No Available Data

What does Imara Inc do?

Who are the key executives at Imara Inc?

Arix Bioscience Holdings Ltd is the 10 percent owner of Imara Inc. Other key executives at Imara Inc include director & President & CEO Rahul D. Ballal , See Remarks Michael Gray , and 10 percent owner Braden Michael Leonard .

Imara Inc (IMRA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Imara Inc (IMRA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Imara Inc (IMRA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Imara Inc (IMRA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Imara Inc Insider Transactions

No Available Data

What does Enliven Therapeutics Inc do?

Who are the key executives at Enliven Therapeutics Inc?

Arix Bioscience Holdings Ltd is the 10 percent owner of Enliven Therapeutics Inc. Other key executives at Enliven Therapeutics Inc include Chief Financial Officer Benjamin Hohl , director & President and CEO Samuel Kintz , and Chief Operating Officer Anish Patel .

Enliven Therapeutics Inc (ELVN) Insider Trades Summary

Over the past 18 months, Arix Bioscience Holdings Ltd made no insider transaction in Enliven Therapeutics Inc (ELVN). Other recent insider transactions involving Enliven Therapeutics Inc (ELVN) include a net sale of 240,342 shares made by Samuel Kintz , a net sale of 239,847 shares made by Joseph P Lyssikatos , and a net sale of 88,314 shares made by Benjamin Hohl .

In summary, during the past 3 months, insiders sold 183,359 shares of Enliven Therapeutics Inc (ELVN) in total and bought 0 shares, with a net sale of 183,359 shares. During the past 18 months, 4,855,709 shares of Enliven Therapeutics Inc (ELVN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 4,855,709 shares.

Enliven Therapeutics Inc (ELVN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Enliven Therapeutics Inc Insider Transactions

No Available Data

Arix Bioscience Holdings Ltd Mailing Address

Above is the net worth, insider trading, and ownership report for Arix Bioscience Holdings Ltd. You might contact Arix Bioscience Holdings Ltd via mailing address: 20 Berkeley Square, London X0 W1j6eq.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.